PTEN and cancer: According to the presented data, we recommend the continuation of enhanced organ-specific cancer surveillance, including in patients with tier 2 germline PTEN variants.21 The consistently elevated lifetime cancer risks compared with more recent studies in the European population8 highlight the need for multiancestry studies that inform standard universal guidelines for PHTS management.